High on-treatment platelet reactivity - why should we be concerned?

References
1 Silber S, Albertsson P, Aviles F. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
2 Wijns W, Kolh P, Danchin N. et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
3 Cattaneo M. High on-treatment platelet reactivity - definition and measurement. Thromb Haemost 2013; 109: 792-798.
4 Bernlochner I, Mayer K, Morath T. et al. Antiplatelet efficacy of prasugrel in patients with high onclopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost 2013; 109: 517-524.
5 Elsenberg EH, van Werkum JW, van de Wal RM. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
6 Goto S, Tomiya A. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?. Thromb Haemost 2013; 109: 177-178.
7 Jaitner J, Stegherr J, Morath T. et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112.
8 Marcucci R, Gori AM, Paniccia R. et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279-286.
9 Saucedo JF, Angiolillo DJ, DeRaad R. et al. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
10 Brouwer MA, Jaspers Focks J, Verheugt FWA. High platelet reactivity - the challenge of prolonged anticoagulation therapy after ACS. Thromb Haemost 2013; 109: 799-807.
11 Dahlen JR, Price MJ, Parise H. et al. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013; 109: 808-816.
12 Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824.
13 Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109: 825-833.
14 Trenk D, Kristensen SD, Hochholzer W. et al. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thromb Haemost 2013; 109: 834-845.
15 Cesari F, Marcucci R, Gori AM. et al. Reticulated platelets predict cardiovascular death in acute coronary syndrom patients. Insights from the AMI-Florence 2 Study. Thromb Haemost 2013; 109: 846-853.
16 Siller-Matula J, Schror K, Wojta J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
17 Höchtl T, Tentzeris I, Schrör K. et al. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundam Clin Pharmacol 2012; 26: 2-10.
18 Yukhanyan L, Freynhofer MK, Siller-Matula J. et al. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 2011; (105) (Suppl. 01) S55-59.
19 Tentzeris I, Siller-Matula J, Farhan S, Jet al. et al. Platelet function variability and non-genetic causes. Thromb Haemost 2011; (105) (Suppl. 01) S60-66.
20 Shuldiner AR, Bilden KP, Gandhi A. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
21 Siller-Matula JM, Jilma B, Schror K. et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 08: 2624-2641.
22 Tentzeris I, Jarai R, Farhan S. et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010; 104: 1211-1218.
23 Freynhofer MK, Bruno V, Wojta J. et al. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18: 5197-5214.
24 Wallentin L, Becker R, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
25 Wiviott S, Trenk D, Frelinger A. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
26 Mega JL, Braunwald E, Wiviott SD. et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
27 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thrombos Haemost 2011; 106: 572-584.
28 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
29 Lip G, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
30 Dewilde W, Oirbasn T, Verheugt FW. et al. The WOEST Trial: First randomised trial comparing two regimens with and without apsirin in patients on oral anticoagulation therapy undergoing coronary stenting. ESC Annual Scientific Session. 2013. August 28 Munich, Germany:
31 Morrow DA, Braunwald E, Bonaca MP. et al. TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
32 Tricoci P, Huang Z, Held C. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
33 Scirica BM, Bonaca MP, Braunwald E. et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012; 380: 1317-1324.
34 Paniccia R, Antonucci E, Maggini N. et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
35 Jeong YH, Bliden KP, Tantry US. et al. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?. J Thromb Haemost 2012; 10: 487-489.
36 Aradi D, Komócsi A, Price MJ. et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol. 2012 Epub ahead of print
37 Schrör K, Huber K, Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 2011; 05: 31-42.
38 Valgimigli M, Tebaldi M, Campo G. et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 05: 268-277.
39 Steg PG, Huber K, Andreotti F. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
40 Kovács EG, Katona E, Bereczky Z. et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res 2013; 131: 320-324.